HC Wainwright Has Positive Forecast for OKUR Q1 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for OnKure Therapeutics in a research note issued to investors on Monday, March 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.05) for the quarter, up from their previous estimate of ($1.15). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.66) EPS.

A number of other analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $27.00.

OnKure Therapeutics Stock Up 3.1%

Shares of OnKure Therapeutics stock opened at $4.02 on Wednesday. OnKure Therapeutics has a 52-week low of $1.70 and a 52-week high of $5.28. The company has a 50 day moving average of $2.88 and a 200 day moving average of $2.89. The company has a market capitalization of $54.46 million, a P/E ratio of -0.91 and a beta of 0.45.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Monday, March 9th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.16.

Institutional Investors Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at about $52,000. ADAR1 Capital Management LLC acquired a new stake in OnKure Therapeutics in the 4th quarter worth about $2,941,000. Kotler Kevin acquired a new stake in shares of OnKure Therapeutics in the fourth quarter worth approximately $573,000. Barclays PLC grew its stake in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the period. Finally, Prosight Management LP grew its position in OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after acquiring an additional 548,950 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.